Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

20/20 Biolabs, Inc. (AIDX) Stock Price & Analysis

14 Followers

AIDX Stock Chart & Stats

$0.23-$0.00(-0.43%)
At close: 4:00 PM EST
$0.2$0.4$0.6Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.22 - $0.25
52-Week Range
$0.21 - $50.00
Previous Close
$0.24
Volume
N/A
Average Volume (3M)
138.07K
Market Cap
$3.14M
Enterprise Value
$4.30M
Total Cash (Recent Filing)
$4.55M
Total Debt (Recent Filing)
$572.45K
Price to Earnings (P/E)
―
Beta
2.74
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

2025 Revenue Rebound

The sharp 2025 revenue rebound indicates renewed demand for the company’s laboratory testing and diagnostic services after the prior decline. If sustained, stronger volume can improve operating leverage, support customer retention, and provide a larger base for rebuilding profitability.

Improved Gross Margin

The year-over-year gross-margin improvement shows that the company retained more revenue after direct costs, which is important for a testing-services model. Further durable margin gains could strengthen cash generation and create a clearer path toward covering operating expenses.

Specialized Diagnostic Business Model

A focused position in infection-prevention testing gives the company a defined healthcare use case rather than an undifferentiated service offering. Its combination of laboratory services and proprietary or branded methods may support repeat customer relationships and commercial expansion.

Bears Say

Persistent Unprofitability

Persistent operating and net losses show that the recent revenue recovery has not yet translated into a sustainable earnings model. The stated cost structure is not scaling with revenue, leaving the company exposed to continued losses until expense control or operating leverage materially improves.

Severe Cash Burn

Several consecutive years of negative operating and free cash flow indicate that reported business activity is not converting into internally generated funding. The especially large 2025 cash burn increases dependence on external capital and can restrict investment in commercial growth.

High Debt And Negative Equity

Extremely high debt combined with negative equity materially weakens financial flexibility and raises refinancing and solvency risk. This capital structure can absorb cash that might otherwise fund operations, while limiting the company’s ability to withstand further volatility.

20/20 Biolabs, Inc. News

AIDX FAQ

What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $0.21 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
20/20 Biolabs, Inc.’s market cap is $3.14M.
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
20/20 Biolabs, Inc. released its earnings results on Aug 17, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.14.
Is 20/20 Biolabs, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 13,367,204 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
20/20 Biolabs, Inc. reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 0.182%.
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology